Rh Antibody Titre
Immunity0 parametersReport in 4HrsAt Home
No Fasting Required
Details
Critical in pregnancy to assess the risk of hemolytic disease of the fetus and newborn (HDFN) caused by Rh incompatibility
₹399₹1,175
66% OFF
FREE:AI Insights
Rh Antibody Titre - Comprehensive Medical Test Guide
- Why is it done?
- Measures the concentration of anti-D (anti-Rh) antibodies in the bloodstream, which are immunoglobulin molecules directed against the RhD antigen found on red blood cells
- Identifies Rh sensitization (alloimmunization) in pregnant women, particularly Rh-negative mothers who may have been exposed to Rh-positive fetal blood
- Assesses risk of hemolytic disease of the newborn (HDN), a serious condition where maternal antibodies attack fetal red blood cells
- Determines the need for anti-D immunoglobulin (RhoGAM) administration in Rh-negative pregnant women
- Evaluates patients with previous Rh sensitization from transfusion of incompatible blood products or previous pregnancy
- Monitors antibody levels throughout pregnancy to predict severity of hemolytic disease and guide clinical management
- Performed at first prenatal visit, 28 weeks of gestation, and with any sensitizing event (trauma, abruption, antepartum hemorrhage)
- Normal Range
- Negative or <0.5 IU/mL (International Units per milliliter): Indicates no detectable anti-D antibodies; absence of Rh sensitization
- Titre reported as ratios (e.g., 1:4, 1:8, 1:16, 1:32): Sequential dilutions showing the maximum dilution at which antibodies are still detectable
- Units of measurement: International Units per milliliter (IU/mL) or titre expression as ratio of dilution
- Normal interpretation: Absence of anti-D antibodies means no prior sensitization to Rh-positive blood or fetal antigens; pregnancy can proceed with standard precautions
- Positive results: Any detectable anti-D antibodies indicate Rh sensitization has occurred; titre level quantifies antibody concentration
- Critical titre threshold: Approximately 1:4 (≥0.5-1 IU/mL) is often considered the critical level above which fetal anemia risk increases significantly
- Interpretation
- Negative Result (<0.5 IU/mL or 1:0): No anti-D antibodies detected; no previous sensitization; Rh-negative patient is not immunized and can safely receive anti-D prophylaxis if needed; low risk for hemolytic disease
- Low Titre (1:2 to 1:4): Mild sensitization present; early stage of immunization; close monitoring recommended; may still be below critical threshold; assess for sources of sensitization
- Moderate Titre (1:8 to 1:16): Significant sensitization; may be approaching or at critical level; moderate risk for fetal anemia; recommended to perform middle cerebral artery (MCA) Doppler ultrasound; consider amniocentesis for amniotic fluid bilirubin assessment
- High Titre (≥1:32): Substantial antibody levels; above critical threshold; high risk for moderate to severe hemolytic disease; definite need for non-invasive fetal monitoring via MCA Doppler; may require intrauterine transfusions; close obstetric follow-up essential
- Rising Titre on Serial Testing: Indicates active immune response and ongoing sensitization; suggests worsening hemolytic disease risk; may result from recent fetomaternal hemorrhage; requires urgent intervention and close monitoring
- Stable Titre on Serial Testing: Indicates chronic sensitization without active immune response; risk remains dependent on absolute titre level; continued monitoring recommended but less frequent than with rising titre
- Factors Affecting Results: - Recent anti-D immunoglobulin administration (may cause passive antibodies) - Time interval since sensitizing event - Volume of fetal-maternal hemorrhage - Individual immune response variation - Presence of complement-binding vs non-complement-binding antibodies - Laboratory testing methodology (indirect antiglobulin test, enzyme techniques, gel technology)
- Associated Organs
- Primary Systems Involved: - Hematologic system: Red blood cells carrying RhD antigen - Immune system: B and T lymphocytes producing anti-D antibodies - Placental system: Site of fetal-maternal hemorrhage - Fetal system: Fetal red blood cells at risk of hemolysis
- Associated Medical Conditions: - Hemolytic disease of the newborn (erythroblastosis fetalis) - Hydrops fetalis (severe fetal edema, ascites, pericardial effusion) - Intrauterine fetal anemia - Kernicterus (bilirubin-induced neurological damage) - Fetal growth restriction - Intrauterine fetal death - Neonatal anemia requiring transfusion
- Conditions Associated with Abnormal Results: - Rh negative maternal status with Rh positive fetal blood exposure - Prior transfusion of incompatible blood products - Placental abruption or preeclampsia with fetal-maternal hemorrhage - Amniocentesis, chorionic villus sampling, or cordocentesis - Intrauterine fetal death with retained fetal tissue - Multiple pregnancy with complications - Ectopic pregnancy rupture - Miscarriage or therapeutic abortion
- Potential Complications from Abnormal Results: - Severe fetal anemia requiring intrauterine transfusion - Hydrops fetalis causing fetal death - Severe neonatal jaundice requiring phototherapy or exchange transfusion - Permanent neurological damage from kernicterus - Fetal or neonatal death - Requirement for intensive neonatal care - Long-term neurodevelopmental complications if severe disease occurs
- Follow-up Tests
- For Negative Results: - Repeat Rh antibody titre at 28 weeks gestation - Kleihauer-Betke test or flow cytometry if any sensitizing event occurs - Administer anti-D immunoglobulin (RhoGAM) at 28 weeks as prophylaxis - Standard prenatal care without special fetal monitoring
- For Low to Moderate Positive Results (1:2 to 1:16): - Serial Rh antibody titre every 2-4 weeks - Middle cerebral artery (MCA) peak systolic velocity Doppler ultrasound - Consider amniocentesis for amniotic fluid bilirubin analysis if titre at or above critical level - Obstetric consultation with maternal-fetal medicine specialist - Specialist fetal assessment
- For High Positive Results (≥1:32): - Serial Rh antibody titre at least every 2 weeks - Weekly or bi-weekly MCA Doppler ultrasound - Amniocentesis with amniotic fluid bilirubin measurement - Cordocentesis (fetal blood sampling) if Doppler suggests fetal anemia - Intrauterine transfusion if significant fetal anemia confirmed - Nonstress testing to assess fetal well-being - Early delivery consideration based on gestational age and fetal condition
- Monitoring Frequency: - First visit: Baseline assessment - 28 weeks: Routine repeat screening - If negative: Standard antenatal care only - If low titre: Every 2-4 weeks or as clinically indicated - If moderate titre: Every 2 weeks with MCA Doppler - If high titre: Every 1-2 weeks with intensive fetal monitoring - After sensitizing event: Within 72 hours
- Related Complementary Tests: - Blood typing (ABO and RhD) for maternal and fetal/neonatal confirmation - Direct antiglobulin test (DAT/Coombs test) on neonatal blood - Kleihauer-Betke test or flow cytometry to quantify fetal-maternal hemorrhage - Indirect antiglobulin test (indirect Coombs) for other alloantibodies - Complete blood count (CBC) for hemoglobin/hematocrit assessment - Reticulocyte count indicating bone marrow response - Serum bilirubin levels in neonatal period - Ultrasound assessment of fetal anatomy and hemodynamics - Doppler studies of fetal cardiovascular function
- Fasting Required?
- Fasting Required: No - fasting is not required for this test
- Food and Fluid Intake: Patient may eat and drink normally before the test; no dietary restrictions apply
- Medications: No medications need to be avoided; continue routine medications as prescribed; inform laboratory of recent anti-D immunoglobulin administration as this may affect interpretation
- Sample Collection: Single venipuncture from arm vein; typically 5-10 mL of blood collected in appropriate tube (usually EDTA or serum separator tube depending on facility protocol)
- Patient Preparation: - Wear comfortable, loose-fitting clothing to facilitate vein access - Inform phlebotomist of any history of difficult venipuncture - Remain seated or reclined during blood draw to prevent dizziness - Drink adequate fluids before collection to improve vein visibility - Inform laboratory of recent blood transfusions or anti-D administration - Provide accurate last menstrual period and delivery date information when applicable - No special timing restrictions; can be drawn at any time of day
- Special Instructions: - Report any recent blood transfusions or suspected transfusion reactions - Disclose all sensitizing events (trauma, abruption, vaginal bleeding, invasive procedures) - Document exact timing of any previous anti-D immunoglobulin dose - Ensure samples are properly labeled with correct patient identifiers - No restriction on physical activity after blood draw - Results typically available within 24-48 hours; some labs offer stat/urgent processing
How our test process works!
